【2h】

Hepatocellular carcinoma

机译:肝细胞癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Primary hepatocellular carcinoma is one of the 10 most common tumours, and the most common primary liver malignancy, in the world. In the majority of cases, it occurs against a background of hepatitis B or C viral infection and/or liver cirrhosis, and is associated with a dismal prognosis of a few months. Current treatments in routine clinical practice are surgical resection and liver transplantation, but these therapies are applicable to only a small proportion of patients and prolongation of survival is restricted. Other treatment options include intra-arterial chemotherapy, transcatheter arterial chemoembolisation, percutaneous ethanol injection, cryotherapy, thermotherapy, proton therapy, or a wide range of their possible combinations. The current lack of definitive data, however, limits the use of these therapies. Another option is gene therapy, which although in its infancy at the present time, may have a significant role to play in the future management of hepatocellular carcinoma.


>Keywords: hepatocellular carcinoma; hepatic resection; liver transplantation; transcatheter arterial chemoembolisation
机译:原发性肝细胞癌是世界上最常见的10种肿瘤之一,也是最常见的原发性肝恶性肿瘤。在大多数情况下,它是在乙型或丙型肝炎病毒感染和/或肝硬化的背景下发生的,并伴有几个月的预后不良。目前在常规临床实践中的治疗方法是手术切除和肝移植,但是这些疗法仅适用于一小部分患者,生存期受到限制。其他治疗选择包括动脉内化疗,经导管动脉化学栓塞,经皮乙醇注射,冷冻疗法,热疗法,质子疗法或多种可能的组合。然而,当前缺乏确定的数据限制了这些疗法的使用。另一选择是基因治疗,尽管目前尚处于起步阶段,但可能在肝细胞癌的未来治疗中起着重要作用。


>关键词:

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号